Sunshine Biopharma Submits Adva-27a Manuscript and Stock Sees Solid Gain (SBFM)

Sunshine Biopharma (OTC: SBFM) rose 16% in today’s over-the-counter market, as the company announced the submission of its Adva-27a manuscript. Sunshine Biopharma opened today’s trading session at a share price of $0.255, touched an intraday high of $0.31 before noon, and eventually traded at $0.29 at the closing bell. Volume traded below average on the other hand, with 58,395 shares exchanging hands.

Today, August 15, 2012, Sunshine Biopharma announced that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal.

The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal, contains a substantial amount of data compiled from experiments conducted by these scientists. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound. Ada-27a has been shown to be effective at killing multidrug-resistant cancer cells in vitro. Multidrug-resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment.

As noted by @pennystock24 on Twitter, Investor Stock Alerts, Investor Ideas, and a few others, promoted Sunshine Biopharma today. There are 11 results found on regarding the promotion of Sunshine Biopharma, with the most recent promotions dated August 1, 2012.

Other notable headlines for Sunshine Biopharma include:

  • August 2, 2012: BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, initiated coverage on Sunshine Biopharma after releasing the latest short sale data through July 31, 2012.
  • July 30, 2012:, an investor research portal specializing in sector research including biotech and pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy Analytics on Sunshine Biopharma and its lead anti-cancer compound, Adva-27a.
  • July 20, 2012: Sunshine Biopharma announced that it had engaged Beta Pharma Canada to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.

Sunshine Biopharma was incorporated on August 31, 2006. It is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The company’s lead compound and drug candidate is Adva-27a, a multi-purpose anti-tumor targeted for various forms of cancer.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.